Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide.
Excellent balance sheet with limited growth.
Share Price & News
How has Quidel's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QL1 has not had significant price volatility in the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: QL1 exceeded the German Medical Equipment industry which returned 17.9% over the past year.
Return vs Market: QL1 exceeded the German Market which returned 2.9% over the past year.
Price Volatility Vs. Market
How volatile is Quidel's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Quidel undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: QL1 (€70.5) is trading above our estimate of fair value (€66.53)
Significantly Below Fair Value: QL1 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: QL1 is poor value based on its PE Ratio (45.4x) compared to the Medical Equipment industry average (35.3x).
PE vs Market: QL1 is poor value based on its PE Ratio (45.4x) compared to the German market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: QL1 is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: QL1 is overvalued based on its PB Ratio (6.1x) compared to the DE Medical Equipment industry average (5.4x).
How is Quidel forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QL1's forecast earnings growth (14.1% per year) is above the savings rate (-0.4%).
Earnings vs Market: QL1's earnings (14.1% per year) are forecast to grow faster than the German market (13.1% per year).
High Growth Earnings: QL1's earnings are forecast to grow, but not significantly.
Revenue vs Market: QL1's revenue (4.2% per year) is forecast to grow slower than the German market (5.1% per year).
High Growth Revenue: QL1's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QL1's Return on Equity is forecast to be low in 3 years time (18.7%).
How has Quidel performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QL1 has high quality earnings.
Growing Profit Margin: QL1's current net profit margins (13.6%) are lower than last year (14.2%).
Past Earnings Growth Analysis
Earnings Trend: QL1 has become profitable over the past 5 years, growing earnings by 73.3% per year.
Accelerating Growth: QL1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: QL1 had negative earnings growth (-1.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (17%).
Return on Equity
High ROE: QL1's Return on Equity (13%) is considered low.
Return on Assets
Return on Capital Employed
How is Quidel's financial position?
Financial Position Analysis
Short Term Liabilities: QL1's short term assets ($222.2M) exceed its short term liabilities ($125.9M).
Long Term Liabilities: QL1's short term assets ($222.2M) do not cover its long term liabilities ($225.2M).
Debt to Equity History and Analysis
Debt Level: QL1's debt to equity ratio (2.3%) is considered satisfactory.
Reducing Debt: QL1's debt to equity ratio has reduced from 56.3% to 2.3% over the past 5 years.
Debt Coverage: QL1's debt is well covered by operating cash flow (1062.2%).
Interest Coverage: QL1's interest payments on its debt are well covered by EBIT (7.2x coverage).
Inventory Level: QL1 has a high level of physical assets or inventory.
Debt Coverage by Assets: QL1's debt is covered by short term assets (assets are 17.6x debt).
What is Quidel's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate QL1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate QL1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QL1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QL1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QL1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Bryant (61yo)
Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice Presid ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD3.42M) is about average for companies of similar size in the German market ($USD2.72M).
Compensation vs Earnings: Doug's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|Chief Financial Officer||8.3yrs||US$1.37m||0.055% $1.6m|
|Senior VP of North America Commercial Operations & General Counsel||14.6yrs||US$1.38m||0.080% $2.3m|
|Senior Vice President of Research & Development||5.8yrs||US$1.58m||0.010% $303.3k|
|Senior Vice President of Distribution||5.1yrs||US$1.49m||0.016% $465.1k|
|Director of Investor Relations||0yrs||no data||no data|
|Senior Vice President of International Commercial Operations||2.3yrs||no data||0.030% $876.7k|
|Senior Vice President of Business Development||4.3yrs||US$1.11m||0.041% $1.2m|
|Senior Vice President of Information Systems & Business Transformation||1yrs||no data||0.0029% $83.7k|
|Secretary||0yrs||no data||no data|
Experienced Management: QL1's management team is seasoned and experienced (5.4 years average tenure).
|Independent Director||5.3yrs||US$161.85k||0.029% $863.5k|
|Independent Chairman||4.5yrs||US$226.34k||0.12% $3.6m|
|Independent Director||1.2yrs||US$58.35k||0.0020% $58.4k|
|Independent Director||4.3yrs||US$160.57k||0.021% $610.1k|
|Independent Director||14yrs||US$152.13k||7.56% $222.0m|
|Independent Director||27yrs||US$152.13k||0.068% $2.0m|
|Director||0.7yrs||no data||no data|
|Independent Director||1.8yrs||US$140.09k||0.052% $1.5m|
Experienced Board: QL1's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QL1 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.
Quidel Corporation's company bio, employee growth, exchange listings and data sources
- Name: Quidel Corporation
- Ticker: QL1
- Exchange: DB
- Founded: 1979
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$3.229b
- Listing Market Cap: US$2.936b
- Shares outstanding: 41.88m
- Website: https://www.quidel.com
Number of Employees
- Quidel Corporation
- 9975 Summers Ridge Road
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|QDEL||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 1983|
|QL1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 1983|
|QBSW||OTCBB (OTC Bulletin Board)||Yes||Common Stock||US||USD||Oct 1983|
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 20:47|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.